Patents by Inventor Guoliang XUN

Guoliang XUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10604502
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 31, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • Patent number: 10590079
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Feng He, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • Publication number: 20190298715
    Abstract: Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 3, 2019
    Inventors: Gregory Motz, Konstantinos John Mavrakias, Jinbiao Liu, Lei Liu, Qiangang Zheng, Guoliang Xun, Qitao Xiao
  • Publication number: 20190092724
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Inventors: Lei DU-CUNY, Feng HE, Qitao XIAO, Guoliang XUN, Qiangang ZHENG
  • Publication number: 20190023684
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Application
    Filed: June 19, 2018
    Publication date: January 24, 2019
    Inventors: Lei DU-CUNY, Qitao XIAO, Guoliang XUN, Qiangang ZHENG
  • Publication number: 20190000880
    Abstract: Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 3, 2019
    Inventors: Gregory Motz, Konstantinos John Mavrakias, Jinbiao Liu, Lei Liu, Qiangang Zheng, Guoliang Xun, Qitao Xiao
  • Patent number: 8507676
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: August 13, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Xingnian Fu, Feng He, Lei Jiang, Yue Li, Fang Liang, Lei Liu, Yuan Mi, Yao-Chang Xu, Guoliang Xun, Xiaoxia Yan, Zhengtian Yu, Ji Yue Zhang
  • Patent number: 8497368
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: July 30, 2013
    Assignee: Novartis AG
    Inventors: Feng He, Miao Dai, Xingnian Fu, Yue Li, Lei Liu, Yuan Mi, Yao-chang Xu, Guoliang Xun, Zhengtian Yu, Ji Yue Zhang
  • Patent number: 8410264
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Xingnian Fu, Feng He, Lei Jiang, Yue Li, Fang Liang, Lei Liu, Yuan Mi, Yao-chang Xu, Guoliang Xun, Xiaoxia Yan, Zhengtian Yu, Ji Yue Zhang
  • Publication number: 20120302570
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: August 6, 2012
    Publication date: November 29, 2012
    Applicant: NOVARTIS AG
    Inventors: Miao DAI, Xingnian FU, Feng HE, Lei JIANG, Yue LI, Fang LIANG, Lei LIU, Yuan MI, Yao-Chang XU, Guoliang XUN, Xiaoxia YAN, Zhengtian YU, Ji Yue ZHANG
  • Publication number: 20120142681
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: August 10, 2010
    Publication date: June 7, 2012
    Applicant: NOVARTIS AG
    Inventors: Feng He, Miao Dai, Xingnian Fu, Yue Li, Lei Liu, Yuan Mi, Yao-chang Xu, Guoliang Xun, Zhengtian Yu, Ji Yue Zhang
  • Publication number: 20110065708
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: August 19, 2010
    Publication date: March 17, 2011
    Applicant: NOVARTIS AG
    Inventors: Miao DAI, Xingnian FU, Feng HE, Lei JIANG, Yue LI, Fang LIANG, Lei LIU, Yuan MI, Yao-chang XU, Guoliang XUN, Xiaoxia YAN, Zhengtian YU, Ji Yue ZHANG